Overview

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

Phase:

PHASE1

Details

Lead Sponsor:

Joseph C. Wu

Treatments:

Artesunate